Compare Cigna Corp (CI) vs Xpeng Inc - ADR (XPEV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cigna Corp vs Xpeng Inc - ADR — how do they compare? Cigna Corp trades at $272.72 (market cap $73.56B), while Xpeng Inc - ADR trades at $11.72 (market cap $11.49B). The key difference: Cigna Corp is far larger — about 6.4× Xpeng Inc - ADR's market cap, and Cigna Corp pays a 2.24% dividend while Xpeng Inc - ADR pays none. Which is the better fit depends on your goals.
| CI | XPEV | |
|---|---|---|
Market Cap | $73.56B | $11.49B |
Sector | Health | Consumer Cyclical |
52-Week High | $311.00 | $28.07 |
52-Week Low | $244.41 | $11.68 |
Enterprise Value | $98.27B | $13.62B |
Dividend Yield | 2.24% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cigna (CI) trades at $282.49, up 2.63% with strong earnings beats in recent quarters. The stock shows bearish technical signals but benefits from low valuation ratios like a P/E of 11.68 and P/S of 0.27. Recent Q2 2026 results exceeded expectations, with EPS of $7.78 beating estimates, and the company raised its full-year guidance to at least $30.45 adjusted EPS, reflecting robust growth in health services and insurance segments.
The outlook is positive due to consistent earnings outperformance and raised guidance, though technical weakness and competitive pressures pose risks. Analyst consensus is strongly bullish with a $338.90 price target, indicating ~20% upside potential from current levels, supported by dividend payments and institutional accumulation.
XPeng (XPEV) trades at $12.13, up 3.85% in the last session, with a bearish technical signal from moving averages but oversold RSI levels. The company reported revenue of $76.72 billion in 2025, with narrowing losses and a negative net income margin of -3.06%. Recent news highlights expansion into robotics and autonomous vehicles, with July 2026 deliveries up 4% year-over-year (PRNewsWire, August 1, 2026).
The outlook is mixed: analyst consensus is bullish with a $17.00 price target (64.7% buy ratings), but risks include persistent losses, high debt-to-asset ratio of 13.63 (2025), and intense EV competition. Upside potential hinges on new model launches and global growth, while cash flow volatility and macroeconomic pressures pose headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cigna Corp
Cigna primarily provides pharmacy benefit management and health insurance services. Its PBM services were greatly expanded by its 2018 merger with Express Scripts and are mostly sold to health insurance plans and employers. Its largest PBM contract is the Department of Defense. In health insurance and other benefits, Cigna mostly serves employers through self-funding arrangements, but it also operates in government programs, such as Medicare Advantage. The company operates mostly in the U.S. with 15 million medical members covered as of the end of 2020, but its services extend internationally, covering another 2 million people.
Read more on CI →About Xpeng Inc - ADR
Founded in 2015, XPeng is a leading Chinese smart electric vehicle, or EV, company that designs, develops, manufactures and markets EVs in China. Its products primarily target the growing base of technology-savvy middle-class consumers in the midrange to high-end segment in China's passenger vehicle market. The company sold over 98,000 EVs in 2021, accounting for about 3% of China's passenger new energy vehicle market. It is also a leader in autonomous driving technology.
Read more on XPEV →
